PMID- 35998681 OWN - NLM STAT- MEDLINE DCOM- 20221130 LR - 20230208 IS - 1879-1891 (Electronic) IS - 0002-9394 (Linking) VI - 244 DP - 2022 Dec TI - Association Between Retinopathy of Prematurity in Very-Low-Birth-Weight Infants and Neurodevelopmental Impairment. PG - 205-215 LID - S0002-9394(22)00312-9 [pii] LID - 10.1016/j.ajo.2022.08.010 [doi] AB - PURPOSE: To evaluate the impact of retinopathy of prematurity (ROP) severity and the treatment of very-low-birth-weight infants (VLBWIs) on neurodevelopmental impairment in early childhood. DESIGN: Prospective cohort study. METHOD: This was a prospective cohort study. The data were obtained from the Korean Neonatal Network (KNN), a nationwide registry for VLBWIs. Infants who were born from 2013 to 2015 and underwent ROP evaluation at birth and neurodevelopmental examinations at corrected ages of 18 to 24 months were included in the study. Infants with a history of meningitis or severe congenital anomalies were excluded. The VLBWI patients were grouped into no ROP, no treatment-requiring ROP (non-TR-ROP), and treatment-requiring ROP (TR-ROP) groups. Neurodevelopmental impairment was defined as participants who had at least 1 developmental problem according to the Bayley Scales of Infant and Toddler Development-2nd Edition (Bayley-II; <70), Bayley Scales of Infant and Toddler Development-3rd Edition (Bayley-III; <70), and Korean Developmental Screening Test (K-DST) tests (below -1 SD), and the Korean Ages and Stages Questionnaire (K-ASQ) (below the threshold) and Gross Motor Function Classification System (GMFCS; at level 2 or above). Multivariable logistic regression analysis was performed to evaluate the association between ROP and neurodevelopmental impairment. RESULT: Among 3132 infants, 1093 (34.9%) had ROP. Among the ROP infants, 644 were not treated for ROP (non-TR-ROP group) and 449 received ROP treatments (TR-ROP group). The patients in the TR-ROP group had an increased risk of developing neurodevelopmental problems compared to those in the no ROP group (odds ratio [OR] = 1.72, 95% CI = 1.33-2.21). The TR-ROP group had a higher risk of all 3 types of neurodevelopmental problems: mental (OR = 1.62, 95% CI = 1.25-2.09), social (OR = 1.62, 95% CI = 1.12-2.09), and motor (OR = 1.69, 95% CI = 1.31-2.18). The risk of neurodevelopmental problems in patients treated with laser therapy did not differ from that in patients treated with anti-vascular endothelial growth factor (anti-VEGF) therapy (OR = 1.17, 95% CI = 0.73-1.88). CONCLUSION: ROP was independently associated with neurodevelopmental impairment in early childhood. The type of ROP treatment (anti-VEGF or laser treatment) did not affect neurodevelopmental impairment in patients in the TR-ROP group. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Han, Gyule AU - Han G AD - From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Lim, Dong Hui AU - Lim DH AD - From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea. FAU - Kang, Danbee AU - Kang D AD - Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Cho, Juhee AU - Cho J AD - Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Guallar, Eliseo AU - Guallar E AD - Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Epidemiology, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Chang, Yun Sil AU - Chang YS AD - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. FAU - Chung, Tae-Young AU - Chung TY AD - From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. FAU - Kim, Sang Jin AU - Kim SJ AD - From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: sangjin.kim.md@gmail.com. FAU - Park, Won Soon AU - Park WS AD - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: wonspark@skku.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220823 PL - United States TA - Am J Ophthalmol JT - American journal of ophthalmology JID - 0370500 SB - IM EIN - Am J Ophthalmol. 2023 Apr;248:179. PMID: 36754746 MH - Child, Preschool MH - Infant, Newborn MH - Infant MH - Humans MH - *Retinopathy of Prematurity/complications/diagnosis/epidemiology MH - Prospective Studies MH - Infant, Very Low Birth Weight MH - *Infant, Newborn, Diseases MH - *Laser Therapy MH - Gestational Age MH - Risk Factors EDAT- 2022/08/24 06:00 MHDA- 2022/12/01 06:00 CRDT- 2022/08/23 19:22 PHST- 2021/11/30 00:00 [received] PHST- 2022/08/07 00:00 [revised] PHST- 2022/08/10 00:00 [accepted] PHST- 2022/08/24 06:00 [pubmed] PHST- 2022/12/01 06:00 [medline] PHST- 2022/08/23 19:22 [entrez] AID - S0002-9394(22)00312-9 [pii] AID - 10.1016/j.ajo.2022.08.010 [doi] PST - ppublish SO - Am J Ophthalmol. 2022 Dec;244:205-215. doi: 10.1016/j.ajo.2022.08.010. Epub 2022 Aug 23.